n/a
Article Publish Status: FREE
Abstract Title:

Pectolinarin Inhibits the Bacterial Biofilm Formation and Thereby Reduces Bacterial Pathogenicity.

Abstract Source:

Antibiotics (Basel). 2022 Apr 29 ;11(5). Epub 2022 Apr 29. PMID: 35625242

Abstract Author(s):

Daseul Kim, Ki-Young Kim

Article Affiliation:

Daseul Kim

Abstract:

Bacterial biofilms are a growing problem as it is a major cause of nosocomial infection from urinary catheters to chronic tissue infections and provide resistance to a variety of antibiotics and the host's immune system. The effect of pectolinarin on the biofilm formation in,,,,,,,, andwas studied in TSBg (tryptic soy broth supplemented with 1% glucose). Pectolinarin inhibited biofilm formation of(IC= 0.39μg/mL),(IC= 0.19μg/mL),(IC= 0.25μg/mL),(IC= 1.2μg/mL),(IC= 1.4μg/mL),(IC= 0.39μg/mL),(IC= 0.9μg/mL),(IC= 12.5μg/mL), and(IC= 9.0μg/mL) without inhibiting the bacterial growth. Pectolinarin also showed increased susceptibility of antibacterial activity with commercially available antibiotics including ampicillin, vancomycin, streptomycin, and oxytetracyclin againstand. Finally, pectolinarin dose-dependently reduced the expression of genes including cytolysin genes (,and), quorum sensing (QS) genes (,,,,,,and), and biofilm virulence genes () ofand. Pectolinarin reduced the bacterial biofilm formation, activated the antibacterial susceptibility, and reduced the bacterial adherence. These results suggest that bacterial biofilm formation is a good target to develop the antibacterial agents against biofilm-related infections.

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.